A1 Refereed original research article in a scientific journal

Restarting anticoagulation early versus late in patients with chronic subdural hematoma and atrial fibrillation (RELACS): a phase III international multicenter, randomized controlled, two-arm, assessor-blinded trial




AuthorsRaj, Rahul; Tommiska, Pihla; Kivisaari, Riku; Korja, Miikka; Luostarinen, Teemu; Virta, Jyri J.; Taimela, Simo; Järvinen, Teppo L.N; Niemelä, Mika; Koivisto, Timo; Leinonen, Ville; Saemundsson, Bjartur; Fletcher-Sandersjöö, Alexander; Korhonen, Tommi; Tetri, Sami; Rauhala, Minna; Laukka, Dan; Czuba, Tomasz; Bartek, Jiri; Danner, Nils; Knuutinen, Oula; Luoto, Teemu; Posti, Jussi P.; Satopää, Jarno

PublisherSpringer Science and Business Media LLC

Publication year2025

Journal: Trials

Article number515

Volume26

Issue1

ISSN1745-6215

eISSN1745-6215

DOIhttps://doi.org/10.1186/s13063-025-09133-w

Publication's open availability at the time of reportingOpen Access

Publication channel's open availability Open Access publication channel

Web address https://doi.org/10.1186/s13063-025-09133-w

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/505441480


Abstract
Background

Chronic subdural hematoma (CSDH) is a rapidly growing neurosurgical condition, driven primarily by an aging population and the increasing use of antithrombotic medications. Approximately 25% of CSDH patients are on anticoagulants due to atrial fibrillation (AF). The postoperative management of these patients presents a significant clinical challenge, as clinicians must balance the risks of thromboembolic and hemorrhagic complications. Currently, no evidence-based guidelines exist regarding the optimal timing for resuming anticoagulation therapy after surgery. This study aims to evaluate the net effect of early versus late postoperative resumption of oral anticoagulation in CSDH patients with AF. We hypothesize that early resumption will result in fewer thromboembolic complications and vascular deaths, without increasing the risk of hemorrhagic complications.

Methods

This is an investigator-initiated, international, multicenter, superiority, two-arm, assessor-blinded, phase 3 trial with 1:1 randomization, comparing early resumption (defined as 5 days) and late resumption (defined as 30 days) of oral anticoagulation medication after CSDH surgery in patients with AF. The primary outcome is a composite outcome that combines thromboembolic events, hemorrhagic events, and vascular death within 90 days of the surgery. Secondary outcomes include reoperations, functional outcome, and adverse events. The estimated sample size is 332 patients to achieve an 80% power and a two-sided alpha of 0.05 for the primary outcome, including potential dropouts.

Discussion

This is the first large-scale RCT addressing the critical evidence gap in anticoagulation timing after CSDH surgery. If early resumption proves superior, it could transform clinical practice by reducing thromboembolic complications without increasing hemorrhagic risk, potentially improving outcomes for the growing population of CSDH patients with AF worldwide.

Trial registration

The study is registered on June 4, 2025. The EU Clinical Trials Register (EUCTR) under identifier EUCT 2025-521179-29-00 (https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2025-521179-29-00).


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
Open Access funding provided by University of Helsinki (including Helsinki University Central Hospital). This study is supported by the State funding for university-level health research (Helsinki University Hospitals), Finska Läkaresällskapet, Medicinska Understödsföreningen Liv & Hälsa, Svenska Kulturfonden and Maire Taponen Foundation. The funding sources will have no role in the collection, analysis and interpretation of data; in the writing of the report and in the decision to submit the article for publication.


Last updated on 2025-28-11 at 14:58